Management of Severe Loss of Appetite in NHL Patients on Lenalidomide and Rituximab

Hematologic Toxicities

• Myelosuppression is the most common grade 3/4 toxicity with lenalidomide, with neutropenia occurring in 43-50% and thrombocytopenia in 28-30% of patients, which may contribute to overall malaise 1, 2

Disease and Treatment Characteristics

• Tumor flare reactions occur in 27-71% of patients on lenalidomide-rituximab combinations, typically manifesting as painful lymphadenopathy, low-grade fever, and rash rather than isolated appetite loss 3, 4